Kalaris Therapeutics (formerly AlloVir)
Houston
About Kalaris Therapeutics (formerly AlloVir)
AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases. It provides an ideal environment for ViraCyte to develop and advance its product pipeline from discovery through late-stage clinical trials.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $410.6M
- Funding stage: M&A
- Last round: Post-IPO Equity (Dec 2025)
- Ticker: nasdaq:ALVR
- Website: allovir.com
- Phone: (346)772-0319
Industries & Categories
Biotechnology, Clinical Trials, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/kalaris-therapeutics-formerly-allovir-49400 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.